Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 11/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163201 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BRPS6KB1HTR6 | |
| SCHEMBL15054204 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BRPS6KB1HTR6 | |
| SCHEMBL15054203 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BRPS6KB1HTR6 | |
| SCHEMBL15054201 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BRPS6KB1HTR6 | |
| Acetic Acid SCHEMBL27904802 | 0.91 | RPS6KB1 (0.46) | RPS6KB1AKT1 | |
| Pivalate SCHEMBL18421815 | 0.87 | AKT1 (0.44) | RPS6KB1AKT1 | |
| SCHEMBL12498168 | 0.85 | HTR2C (0.49) | HTR2AHTR2CHTR2BTAAR1 | |
| Tert-Butyl Formate SCHEMBL18421816 | 0.85 | AKT1 (0.40) | HTR2AHTR2CHTR2BRPS6KB1HTR6 | |
| Tert-Butyl Formate SCHEMBL27904776 | 0.85 | AKT1 (0.40) | HTR2AHTR2CHTR2BRPS6KB1HTR6 | |
| SCHEMBL22958180 | 0.81 | HTR6 (0.43) | HTR2AHTR2CHTR2BRPS6KB1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| CN-104169258-A | Novel heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH | 2014-11-26 | — | — | CN | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | HTR2A 2916/4885HTR2C 2087/4885HTR2B 2564/4885 |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MAP3K19, MAP3K15, MAP3K12 | HTR2A 2971/4885HTR2C 2256/4885HTR2B 2495/4885 |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MAP3K15, MAP3K12, MAP3K11 | HTR2A 2916/4885HTR2C 2248/4885HTR2B 2719/4885 |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | HTR2A 2971/4885HTR2C 2256/4885HTR2B 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.